Corcept Faces Lawsuit Over Alleged Misleading FDA Drug Statements

NEW YORK, NY – February 25, 2026 – Corcept Therapeutics Incorporated is now at the center of a legal firestorm as a class action lawsuit alleges the company and its leadership made materially false and misleading statements to investors regarding the approval prospects of its key drug candidate, relacorilant. The lawsuit, filed by the DJS Law Group, claims the biopharmaceutical firm painted an overly optimistic picture of the drug's path to market, culminating in a catastrophic stock price collapse that erased significant shareholder value overnight.

The legal action follows Corcept's stunning December 31, 2025, disclosure that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for relacorilant's application in treating Cushing's syndrome. The news sent the company’s stock (NASDAQ: CORT) plummeting by approximately 50%, prompting intense scrutiny from investors who now question what management knew and when they knew it.

The Heart of the Allegation: A Drug's Troubled Path

The class action complaint, which covers investors who purchased CORT shares between October 31, 2024, and December 30, 2025, accuses Corcept of violating federal securities laws, specifically §§10(b) and 20(a) of the Securities Exchange Act of 1934. At its core, the lawsuit alleges a fundamental disconnect between the company's public pronouncements and its private communications with regulators.

According to the complaint, Corcept repeatedly assured the market that relacorilant was “approaching approval” based on what it termed “powerful evidence” from its clinical trials. However, the lawsuit contends that these statements were deceptive because the FDA had allegedly warned the company “on several occasions” that its clinical data for the Cushing's syndrome application was insufficient. A Complete Response Letter from the FDA signifies that the agency has completed its review of a drug application and determined that it cannot be approved in its present form, outlining specific deficiencies that must be addressed.

The issuance of the CRL on the last day of 2025 served as the catalyst that brought these alleged discrepancies to light. For investors who had bought into the company's confident narrative, the sudden reversal was devastating. The lawsuit seeks to recover damages for shareholders who suffered losses due to the stock's sharp decline, with a deadline of April 21, 2026, for interested parties to seek appointment as lead plaintiff.

Relacorilant is a critical component of Corcept's future strategy. It was developed as a next-generation cortisol modulator intended to succeed the company's sole marketed product, Korlym, by offering a similar therapeutic benefit for Cushing's syndrome without some of Korlym's more challenging side effects. The CRL has now placed the timeline for this succession plan in serious jeopardy.

Financial Fallout and Investor Scrutiny

The market’s reaction to the relacorilant setback was swift and severe, but it compounded existing financial pressures. The company's fourth-quarter 2025 financial results, reported on February 24, 2026, revealed that revenue and net income both fell short of analyst expectations. The firm reported Q4 revenue of $202.1 million, missing the consensus estimate of $249.5 million. Management attributed the shortfall to operational disruptions during a transition to a new specialty pharmacy vendor, even as it noted a record number of new prescriptions for its existing business.

Despite the revenue miss, Corcept issued revenue guidance for fiscal year 2026 between $900 million and $1 billion. While representing potential growth, the midpoint of this guidance landed slightly below what analysts had been projecting, adding to investor unease. The company's cash and investment reserves also saw a decline, dropping from $603.2 million at the end of 2024 to $532.4 million by the end of 2025.

This combination of a major regulatory setback and underwhelming financial performance has put Corcept under a microscope. The lawsuit amplifies this pressure, suggesting that the company's challenges may extend beyond operational hiccups to fundamental issues of corporate transparency and governance. The involvement of multiple law firms now investigating or filing similar claims indicates a broad base of investor discontent.

A Tale of Two Trials: Relacorilant's Mixed Fortunes

While the outlook for relacorilant in Cushing's syndrome is now clouded by uncertainty, the drug’s story is not over. In a parallel development that adds a layer of complexity to Corcept’s situation, relacorilant is also being evaluated in a pivotal Phase 3 trial, known as ROSELLA, for an entirely different indication: treating platinum-resistant ovarian cancer in combination with chemotherapy.

Unlike the Cushing's syndrome application, the ROSELLA trial has yielded positive news. Corcept has previously announced that the trial successfully met its primary endpoint of improving overall survival for patients. This promising data has led to a separate FDA review process for the cancer indication, with a scheduled Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026. This means the FDA is expected to make an approval decision for this specific use by that date.

The dual tracks of relacorilant's development create a high-stakes scenario for Corcept. A potential approval in oncology could provide a significant new revenue stream and partially offset the disappointment and delay from the Cushing's syndrome CRL. However, the legal battle and the questions it raises about the company's communications with regulators could cast a shadow over any future success.

For now, Corcept must navigate a multi-front challenge: defending itself against serious legal allegations, working with the FDA to determine a path forward for relacorilant in Cushing's syndrome, and anxiously awaiting the agency's verdict on its use in ovarian cancer. The outcome of these converging events will undoubtedly define the company's trajectory for years to come.